3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
8
Neoplasms by Site
4
Digestive System Neoplasms
4
Pancreatic Neoplasms
3
Neoplasms, Glandular and Epithelial
3
Digestive System Diseases
3
Colorectal Neoplasms
3
Pancreatic Diseases
2
Neoplasms by Histologic Type
2
Endocrine Gland Neoplasms
2
Carcinoma, Pancreatic Ductal
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Hepatocellular
2
Adenocarcinoma
2
Thymus Neoplasms
1
Thoracic Neoplasms
1
Stomach Neoplasms
1
Respiratory Tract Neoplasms
1
Rectal Diseases
1
Previously Treated Metastatic Colorectal Cancer
1
Pancreatic cancer, adult
1
Multiple Myeloma
1
Mesothelioma, Malignant
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Intestinal Neoplasms
1
Intestinal Diseases
1
Interventions
Carboplatin
8
Pemetrexed
6
pembrolizumab
5
osimertinib
4
entinostat
3
Paclitaxel
3
Gemcitabine
3
selpercatinib
2
pralsetinib
2
durvalumab
2
Erlotinib Hydrochloride
2
Cisplatin
2
taletrectinib
1
sotorasib
1
repotrectinib
1
patritumab
1
necitumumab
1
napabucasin
1
ficlatuzumab
1
exemestane
1
efineptakin alfa
1
cobimetinib
1
ceralasertib
1
camrelizumab
1
atezolizumab
1
alectinib
1
Vinorelbine
1
TNFSF10 protein, human
1
Patient Reported Outcome Measures
1
Nivolumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Thoracic Neoplasms
×
napabucasin
×
Clear all
NCT02826161
2023-11-15
CanStem43L
Sumitomo Pharma America, Inc.
Phase 3
Terminated
4 enrolled
6 charts